Ixekizumab (Taltz) for plaque psoriasis: Positive opinion by the European CHMP

March 04, 2016 –  On February 25, 2016, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Ixekizumab (Taltz), intended for the treatment of plaque IL-17A Inhibitorspsoriasis. Ixekizumab (Taltz) will be available as a 80 mg solution for injection. The active substance of Taltz,  Ixekizumab, is an immunosuppressant. Ixekizumab is a monoclonal antibody that binds with high affinity and specificity to both forms of interleukin 17A (IL‑17A and IL‑17A/F). Neutralisation of IL‑17A by Ixekizumab inhibits keratinocyte proliferation and activation which have been implicated in the pathogenesis of psoriasis.

The benefits with Ixekizumab (Taltz) are its statistically significant and clinically relevant effects compared to placebo or etanercept in terms of ‘Psoriasis Area and Severity Index’ (PASI) score 75 and ‘static Physician Global Assessment of 0 or 1 (sPGA (0/1)) at week 12. PASI 90, PASI 100 and sPGA 0 response rates indicating nearly complete/complete clearance were also statistically significantly better with Taltz compared to placebo or Etanercept (Enbrel).

The most frequently reported adverse drug reactions were upper respiratory tract infections. Most of the reactions were mild or moderate in severity.The full indication is: “Taltz is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy”. It is proposed that Taltz is prescribed by physicians experienced in the treatment and diagnosis of psoriasis.

Detailed recommendations for the use of this product will be described in the summary of product characteristics (SmPC), which will be published in the European public assessment report (EPAR) and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

The mode of action of Ixekizumab (Waltz) is very similar if not identical to that of Secukinumab (Cosentyx), which has earlier been approved by both the American Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of plaque psoriasis as well. Both, Ixekizumab and Secukinumab are monoclonal antibodies that bind and inhibit IL 17A.

Tags: , , , , , , ,
About the Author
Joseph Gut - thasso Ph.D.; Professor in Pharmacology and Toxicology. Senior expert in theragenomic and personalized medicine and individualized drug safety. Senior expert in pharmaco- and toxicogenetics. Senior expert in human safety of drugs, chemicals, environmental pollutants, and dietary ingredients.

Your opinion

Comment

@peepso_user_31663(MPHO) Fellow ALS patients, I’m taking DR JOE ALS(Amyotrophic Lateral Sclerosis)HERBAL FORMULA daily for 6 weeks and 5 days now. 2 to 4 weeks after I started this treatment my ALS progress stopped and my health condition start’s to improve. I continued with this treatment and during this time I achieved more and more improvement- My hands and legs are much stronger, my breathing is much better and many other things improved much. THIS FORMULA HAS SUCCESSFULLY STOPPED AND REVERSED MY ALS !!!!
I advise you to contact DR JOE India or SA branch via his webpage: ww w. besthealthherbalcentre .c om
@peepso_user_31991(mofoso) My first symptoms of ALS occurred in 2011, but was diagnosed in 2013. I had severe symptoms ranging from shortness of breath, balance problems, couldn't walk without a walker or a power chair, i had difficulty swallowing and fatigue. I was given medications which helped but only for a short burst of time, then i decided to try alternative measures and began on ALS Formula treatment from Akanni herbal centre , It has made a tremendous difference for me (Visit www. akanniherbalcentre .com). I had improved walking balance, increased appetite, muscle strength, improved eyesight and others. 

thasso: conditions

thasso: newest tweets

thasso: recent comments

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • BICRA gene provides answers to patients, doctors and scientists November 23, 2020
    Physicians and scientists are constantly on the lookout for new disease genes that can help them understand why patients have undiagnosed medical problems. Often the first clues come from genetic testing that reveals a change or mutation in a gene that they see in a child but not their parents. This is exactly what led […]
  • New targeted therapy blocks metabolism in brain cancer cells with genetic vulnerability November 23, 2020
    Researchers at The University of Texas MD Anderson Cancer Center have developed a novel targeted therapy, called POMHEX, which blocks critical metabolic pathways in cancer cells with specific genetic defects. Preclinical studies found the small-molecule enolase inhibitor to be effective in killing brain cancer cells that were missing ENO1, one of two genes encoding the […]
  • Major new study unveils complexity and vast diversity of Africa's genetic variation November 23, 2020
    Africa is the cradle of humankind. All humans are descendants from this common pool of ancestors. Africa and its multitude of ethnolinguistic groups are therefore fundamental to learning more about humankind and our origins.
  • Targeting drug-resistant cancers through mathematical biology to control gene expression November 23, 2020
    Among the things to give thanks for this year is the fact that stubborn, persistent problems seem to have an irresistible sort of magnetic pull for scientists and mathematicians. Things that would leave most of us bewildered are their daily bread.
  • Study finds hyperbaric oxygen treatments reverse aging process November 20, 2020
    A new study from Tel Aviv University (TAU) and the Shamir Medical Center in Israel indicates that hyperbaric oxygen treatments (HBOT) in healthy aging adults can stop the aging of blood cells and reverse the aging process. In the biological sense, the adults' blood cells actually grow younger as the treatments progress.
  • In fire-prone West, plants need their pollinators -- and vice versa November 25, 2020
    A new study grounded in the northern Rockies explores the role of wildfire in the finely tuned dance between plants and their pollinators. Previous studies have looked at how fire affects plants, or how fire affects animals. But what is largely understudied is the question of how fire affects both, and about how linkages within […]
  • Waste fishing gear threatens Ganges wildlife November 25, 2020
    Waste fishing gear in the River Ganges poses a threat to wildlife including otters, turtles and dolphins, new research shows.
  • When consumers trust AI recommendations--or resist them November 25, 2020
    The key factor in deciding how to incorporate AI recommenders is whether consumers are focused on the functional and practical aspects of a product (its utilitarian value) or on the experiential and sensory aspects of a product (its hedonic value).
  • Shining a light on nanoscale dynamics November 24, 2020
    Watching metamaterials at work in real time using ultrafast electron diffraction: a research team led by University of Konstanz physicist Peter Baum succeeds in using ultrashort electron pulses to measure light-matter interactions in nanophotonic materials and metamaterials.
  • Guiding the way to improved solar cell performance November 24, 2020
    Small molecules could hold the key to enhancing the efficiency of organic solar cells.
Top